You’ll find research from the Witkiewicz-Knudsen Lab in prominent cancer journals, including Frontiers in Oncology, Cancer Discovery, Trends in Cancer, Oncogene, Cell Reports and more.
CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities
- Journal: Cell Reports, March 2022
- Authors: Knudsen ES, Kumarasamy V, Nambiar R, Pearson JD, Vail P, Rosenheck H, Wang J, Eng K, Bremner R, Schramek D, Rubin SM, Welm AL, Witkiewicz AK
- Citation: Cell Rep. 2022 Mar 1;38(9):110448. doi: 10.1016/j.celrep.2022.110448
Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center
- Journal: The Oncologist, August 2022
- Authors: Knudsen ES, Schultz E, Hamilton D, Attwood K, Edge S, O'Connor T, Levine E, Witkiewicz AK
- Citation: Oncologist. 2022 Aug 5;27(8):646-654. doi: 10.1093/oncolo/oyac089
- Kumarasamy V, et al. The extracellular niche and tumor microenvironment enhance KRAS inhibitor efficacy in pancreatic cancer. Cancer Res. 2024 Jan 31. doi: 10.1158/0008-5472.CAN-23-2504.
- Kumarasamy V, et al. Pharmacologically targeting KRAS G12D in PDAC models: tumor cell intrinsic and extrinsic impact. bioRxiv [Preprint]. 2023 Apr 20:2023.03.18.533261. doi: 10.1101/2023.03.18.533261. PMID: 37162905; PMCID: PMC10168422.
- Matsukawa T, et al. Mcm2 hypomorph leads to acute leukemia or hematopoietic stem cell failure, dependent on genetic context. FASEB J. 2022 Sep;36(9):e22430. doi: 10.1096/fj.202200061RR. PMID: 35920299; PMCID: PMC9377154.
- Langille E, et al. Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer. Cancer Discov. 2022 Dec 2;12(12):2930-2953. doi: 10.1158/2159-8290.CD-21-0865. PMID: 36108220; PMCID: PMC9812400.
- Kumarasamy V, et al. RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models. Oncogene. 2022 Jul;41(27):3524-3538. doi: 10.1038/s41388-022-02362-2. Epub 2022 Jun 9. PMID: 35676324.
- Finnegan RM, et al. The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer. Front Oncol. 2023 Jan 18;12:966441. doi: 10.3389/fonc.2022.966441. PMID: 36741704; PMCID: PMC9890056.
Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy
- Journal: Trends in Cancer, September 2022
- Authors: Witkiewicz AK, Kumarasamy V, Sanidas I, Knudsen ES
- Citation: Trends Cancer. 2022 Sep;8(9):711-725. doi: 10.1016/j.trecan.2022.04.006
Contact the Witkiewicz-Knudsen Lab
Department of Molecular and Cellular Biology
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263